These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35524809)

  • 21. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.
    Zhang WX; Chen B; Jin Z; Yu Z; Wang X; Chen H; Mao A; Cai W
    Xenobiotica; 2008 Nov; 38(11):1422-36. PubMed ID: 18946804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics.
    Wu TY; Peng Y; Pelleymounter LL; Moon I; Eckloff BW; Wieben ED; Yee VC; Weinshilboum RM
    Br J Pharmacol; 2010 Dec; 161(7):1584-98. PubMed ID: 20718729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malnutrition Risk in Kidney Recipients Treated With Mycophenolate Mofetil Is Associated With IMPDH1 rs2278294 Polymorphism.
    Pazik J; Lewandowski Z; Nowacka Cieciura E; Ołdak M; Podgórska M; Sadowska A; Dęborska Materkowska D; Durlik M
    Transplant Proc; 2018; 50(6):1794-1797. PubMed ID: 30056902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients.
    Sánchez-Fructuoso AI; Maestro ML; Calvo N; Viudarreta M; Pérez-Flores I; Veganzone S; De la Orden V; Ortega D; Arroyo M; Barrientos A
    Transplant Proc; 2009; 41(6):2313-6. PubMed ID: 19715905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacogenetics of mycophenolate mofetil in Tunisian renal transplant patients.
    Abderahmene A; Ellouz A; Amor D; Ajmi M; Khalij Y; Hamdouni H; Sahtout W; Azzabi A; Omezzine A; Achour A; Bouslama A
    Per Med; 2022 Sep; 19(5):383-393. PubMed ID: 35770851
    [No Abstract]   [Full Text] [Related]  

  • 26. Lack of Association between Interleukin-10 Gene Polymorphisms and Graft Rejection Risk in Kidney Transplantation Recipients: A Meta-Analysis.
    Xiong J; Wang Y; Zhang Y; Nie L; Wang D; Huang Y; Feng B; Zhang J; Zhao J
    PLoS One; 2015; 10(6):e0127540. PubMed ID: 26035439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.
    Johnson LA; Oetting WS; Basu S; Prausa S; Matas A; Jacobson PA
    Eur J Clin Pharmacol; 2008 Nov; 64(11):1047-56. PubMed ID: 18568343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression.
    Bremer S; Mandla R; Vethe NT; Rasmussen I; Rootwelt H; Line PD; Midtvedt K; Bergan S
    Transplantation; 2008 Jan; 85(1):55-61. PubMed ID: 18192912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome.
    Shah S; Harwood SM; Döhler B; Opelz G; Yaqoob MM
    Transplantation; 2012 Sep; 94(5):486-91. PubMed ID: 22960765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
    Staatz CE; Tett SE
    Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients.
    Cilião HL; Camargo-Godoy RBO; de Souza MF; Dos Reis MB; Iastrenski L; Alvares Delfino VD; Rogatto SR; de Syllos Cólus IM
    J Toxicol Environ Health A; 2017; 80(13-15):661-671. PubMed ID: 28524801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppression.
    Penezić L; Nađ-Škegro S; Hadžavdić A; Ganoci L; Kaštelan Ž; Trkulja V; Božina N
    Pharmacogenomics J; 2024 May; 24(3):15. PubMed ID: 38769303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of
    Jiang Z; Hu N
    Pharmacogenomics; 2021 Oct; 22(15):1019-1040. PubMed ID: 34581204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients.
    Jung HY; Lee S; Jeon Y; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
    J Korean Med Sci; 2020 Jun; 35(24):e185. PubMed ID: 32567256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
    Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients.
    Krall P; Yañez D; Rojo A; Delucchi Á; Córdova M; Morales J; Boza P; de la Rivera A; Espinoza N; Armijo N; Castañeda LE; Farfán MJ; Salas C
    Front Pharmacol; 2021; 12():653525. PubMed ID: 33967795
    [No Abstract]   [Full Text] [Related]  

  • 37. Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients.
    Molinaro M; Chiarelli LR; Biancone L; Castagneto M; Boschiero L; Pisani F; Sabbatini M; Sandrini S; Arbustini E; Tinelli C; Regazzi M; Schena FP; Segoloni GP
    Drug Metab Pharmacokinet; 2013; 28(2):109-17. PubMed ID: 22892445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients.
    Md Dom ZI; Coller JK; Carroll RP; Tuke J; McWhinney BC; Somogyi AA; Sallustio BC
    Br J Clin Pharmacol; 2018 Oct; 84(10):2433-2442. PubMed ID: 29974488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients.
    Genvigir FDV; Nishikawa AM; Felipe CR; Tedesco-Silva H; Oliveira N; Salazar ABC; Medina-Pestana JO; Doi SQ; Hirata MH; Hirata RDC
    Pharmacotherapy; 2017 May; 37(5):535-545. PubMed ID: 28316087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
    Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
    Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.